Trailing-twelve-month (TTM) revenue is $3.41 Billion with a year-over-year growth of +11.20%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $776,133,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-28 |
| Q4 FY2025Period ended 2025-12-31 | $874,565,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $766,208,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $989,708,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $3,406,614,000 |
Current P/S: $10,880,922,780 market capitalization ÷ $3,406,614,000 TTM revenue = 3.19x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T14:20:14.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $989.71M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:21:01.798Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2020-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Enzyme Product | N/A | N/A | N/A | $1.7B | N/A | N/A |
| Product | N/A | $1.8B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20152015-12-31 · USD | FY20162016-12-31 · USD | FY20172017-12-31 · USD | FY20182018-12-31 · USD | FY20192019-12-31 · USD | FY20202020-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $179M | $253M | $301M | $436M | $509M | $518M |
| Latin America | $142M | $147M | $182M | $185M |
$3.41B
$3.41 Billion
+11.20%
vs. $3.06B a year ago (TTM)
+12.19%
5 Year compound annual growth rate
1 Year
+11.20%
3 Year
+15.09%
5 Year
+12.19%
10 Year
+13.34%
15 Year
+14.98%
20 Year
+22.99%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $3.22B | +$367.34M | +12.87% |
| 2024 | $2.85B | +$434.69M | +17.97% |
| 2023 | $2.42B | +$323.19M | +15.42% |
| 2022 | $2.10B | +$249.76M | +13.53% |
| 2021 | $1.85B | ($14.18M) | (0.76%) |
| 2020 |
TTM Growth
+11.20%
3-Year CAGR
+15.09%
5-Year CAGR
+12.19%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T14:21:01.798Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $2.4B |
| $2.8B |
| $3.2B |
| Royalty And Other | $55M | $63M | $54M | $47M | $44M | $53M |
|---|
| $206M |
| Rest Of World | $125M | $209M | $241M | $173M | $198M | $224M |
|---|
| U S | $444M | N/A | N/A | N/A | N/A | N/A |
|---|
| UNITED STATES | N/A | $508M | $588M | $697M | $778M | $912M |
|---|
| $1.86B |
| +$156.41M |
| +9.18% |
| 2019 | $1.70B | +$212.79M | +14.27% |
| 2018 | $1.49B | +$177.61M | +13.52% |
| 2017 | $1.31B | +$196.79M | +17.62% |
| 2016 | $1.12B | +$226.96M | +25.50% |
